Guidance on brolucizumab management recommendations.
A Fonollosa1, R Gallego-Pinazo2, L Sararols3
1Servicio de Oftalmología, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain; Instituto Oftalmológico Bilbao, Bilbao, Spain.
Archivos De La Sociedad Espanola De Oftalmologia
|July 26, 2022
Summary
Brolucizumab, an anti-VEGF drug for AMD, shows efficacy but carries risks of intraocular inflammation (IOI). New recommendations aim to guide safe clinical use and minimize vision loss from adverse events.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacology
Background:
- Brolucizumab, a novel anti-VEGF agent, demonstrated efficacy in AMD clinical trials.
- Post-marketing surveillance identified adverse events, including intraocular inflammation (IOI).
- A post hoc analysis indicated an IOI rate of 4.6% in pivotal trials.
Purpose of the Study:
- To propose recommendations for managing brolucizumab in clinical practice.
- To ensure patient safety and minimize vision loss from adverse events.
- To guide retinologists in the routine use of brolucizumab.
Main Methods:
- Clinical experience of the authors.
- Critical review of pivotal trial data.
- Analysis of post-hoc data and published literature.
Main Results:
- Brolucizumab demonstrated sustained visual gains and anatomical improvements in trials.
- Post-marketing adverse events include retinal vasculitis and vascular occlusion.
- Recommendations include patient screening, monitoring, and prompt treatment of adverse events.
Conclusions:
- Adverse events, though rare, can cause severe vision loss.
- Recommendations aim to facilitate brolucizumab management and patient safety.
- Minimizing the impact of adverse events on vision is a key objective.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
175
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
175
01:26Atherosclerosis III: Management
31
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
31
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
224
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
224
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.7K
01:26Peptic Ulcer Disease IV: Management
141
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
141
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
259
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
259